Hyperprolactinaemia in antipsychotic-treated patients: Guidelines for avoidance and management

CNS Drugs

Volumn 10, Issue 3, 1998, Pages 209-222

  Hamner, Mark B ^a,b   Arana, George W ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

DRUG EFFECT; HUMAN; HYPERPROLACTINEMIA; PRIORITY JOURNAL; PROLACTIN RELEASE; PSYCHOSIS; REVIEW;

EID: 0031750942     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199810030-00005     Document Type: Review

References (69)

1. Daniels GH, Martin JB. Neuroendocrine regulation and diseases of the anterior pituitary and hypothalamus. In: Wilson JD, Braunwald E, Isselbecherk J, et al., editors. Harrison's principles of internal medicine. New York: McGraw-Hill, 1995
2. Arana GW, Boyd AE, Reichlin S, et al. Prolactin levels in mild depression. Psychosom Med 1977; 39: 193-6
3. Mangurian LP, Walsh RJ, Posner BI. Prolactin enhancement of its own uptake at the choroid plexus. Endocrinology 1992; 131 (2): 698-702
4. Maes M, Meltzer M. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 933-4
5. Signs SA, Bing L, Wolford J, et al. Serotonergic involvement in the regulation of prolactin and vasoactive intestinal peptide mRNA expression in the rat anterior pituitary. Mol Cell Endocrinol 1994; 105: 183-91
6. Flores CM, Hulihan-Giblin BA, Hornby PJ, et al. Partial characterization of a neurotransmitter pathway regulating the in vivo release of prolactin. Neuroendocrinology 1992; 35: 519-28
7. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25: 390-2
8. Meltzer HY, Nash JF. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 1991; 43: 587-604
9. Meltzer HY, Fang VS. Effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976; 33: 279-86
10. Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992; 11: 851-6
11. Goebel S, Dietrich M, Jarry H, et al. Indirect evidence to suggest that prolactin mediates the adrenal action of haloperidol to stimulate aldosterone and corticosterone secretion in rats. Endocrinology 1992; 139 (2): 914-9
12. Klibanski A, Need RM, Beitins IZ, et al. Decreased bone density in hyperprolactinemic women. N Engl J Med 1980; Dec 26: 1511-4
13. Halbreich U, Palter S. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull 1996; 22 (3): 447-54
14. Schyve P, Smithline F, Meltzer HY. Neuroleptic-induced prolactin elevation and breast cancer: an emerging clinical issue. Arch Gen Psychiatry 1978; 25: 1291-301
15. Wang DY, Stepniewska KA, Allen DS, et al. Serum prolactin levels and their relationship to survival in women with operable breast cancer. J Clin Epidemiol 1995; 48 (7): 959-68
16. 5-steroids in tumorigenesis. Int J Cancer 1992; 50: 854-8
17. Halbreich U, Shen J, Panaro V. Are chronic psychiatric patients at increased risk for developing breast cancer? Am J Psychiatry 1996; 153 (4): 559-60
18. Windgassen K, Wesselmann U, Schulze-Mönking H. Galactorrhea and hyperprolactinemia in schizophrenia patients on neuroleptics: frequency and etiology. Neuropsychobiology 1996; 33: 142-6
19. Wesselmann U, Windgassen J. Galactorrhea: subjective response by schizophrenic patients. Acta Psychiatr Scand 1995; 91: 152-5
20. Zito JM, Sofair JB, Jaeger J. Self-reported neuroendocrine effects of antipsychotics in women: a pilot study. Ann Pharmacother 1990; 24: 176-80
21. Meltzer HY. Effect of psychotropic drugs on neuroendocrine function. Psychiatr Clin North Am 1980; 3: 277-98
22. Beaumont PJV, Gelder MG. The effects of phenothiazines on endocrine function: 1. Patients with inappropriate lactation and amenorrhoea. Br J Psychiatry 1974; 124: 413-9
23. Green AI, Brown WA. Prolactin and neuroleptic drugs. Neurol Clin 1988; 6(1): 213-23
24. Van Putten T, Marder SR, Mintz J. Serum prolactin as a correlate of clinical response to haloperidol. J Clin Psychopharmacol 1991; 11 (6): 357-61
25. Meltzer HY, Daniels S, Fang VS. Clozapine increases rat serum prolactin levels. Life Sci 1975; 17: 339-42
26. Meltzer HY, Goode DJ, Schyve PM, et al. Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1979; 136: 1550-5
27. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96
28. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324 (11): 746-54
29. Sachar EJ, Gruen PH, Altman N, et al. Use of neuroendocrine techniques in psychopharmacological research. In: Sachar EJ, editor. Hormones, behavior, and psychopathology. New York: Raven Press, 1976: 161-7
30. Nair NPV, Lal S, Cervantes P, et al. Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia. Neuropsychobiology 1979; 5: 136-42
31. Szymanski S, Lieberman J, Pollack S, et al. Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: preliminary findings. Biol Psychiatry 1995; 37: 52-5
32. Owen RR, Gutierrez-Esteinou R, Hsiao J, et al. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. Arch Gen Psychiatry 1993; 50: 636-44
33. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. rev. Washington, DC: American Psychiatric Association, 1987
34. Lee HS, Kim CH, Song DH, et al. Clozapine does not elevate serum prolactin levels in healthy men. Biol Psychiatry 1995; 38: 762-4
35. Gudelsky GA, Meltzer HY. Activation of tuberoinfundibular neurons following the acute administration of atypical antipsychotics. Neuropsychopharmacology 1989; 2: 45-51
36. Meltzer HY, Maes M, Lee MA. The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine. Psychopharmacology 1993; 112: S95-104
37. Bowden CR, Voina SJ, Woestenborghs R, et al. Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vivo. J Pharmacol Exp Ther 1992; 262: 699-706
38. Huang M-L, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54 (3): 257-68
39. Otton SV, Schadel M, Cheung SW, et al. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993; 54: 463-72
40. Dickson RA, Dalhy JT, Williams R, et al. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry 1995 Jul; 152: 1102-3
41. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multicentre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712-26
42. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13 (1): 25-40
43. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-35
44. Kleinberg DL, Brecher M, Davis JM. Prolactin levels and adverse events in patients treated with risperidone. 6th World Congress of Biological Psychiatry; 1997 Jun 22-27; Nice
45. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 120: 67-74
46. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997; 16: 1-7
47. Beasley C, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111-23
48. Crawford AMK, Beasley Jr CM, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997; 26: 41-54
49. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154 (4): 457-65
50. Saller CR, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993; 112: 285-92
51. Goldstein JM. Preclinical profile of Seroquel (quetiapine): an atypical antipsychotic with clozapine-like pharmacology. In: Holliday SG, Ancill RJ, MacEwan GW, editors. Schizophrenia: breaking down the barrier. New York: John Wiley & Sons, 1996: 209-36
52. Wetzel H, Szegedi A, Hain Ch, et al. Seroquel (ICI 204,636), a putative 'atypical' antipsychotic in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacology 1995; 119: 231-8
53. Hamner MB, Arvanitis L, Miller B, et al. Plasma prolactin in schizophrenic subjects treated with Seroquel™ (ICI 204,636). Psychopharmacol Bull 1996; 32: 107-10
54. Hamner MB, Arvanitis LA, Miller BG, et al. Plasma prolactin in schizophrenic patients treated with Seroquel. Biol Psychiatry 1995; 37: 683
55. Arvanitis LA. Clinical profile of Seroquel™ (quetiapine): an overview of recent clinical studies. In: Holliday SG, Ancill RJ, MacEwan GW, editors. Schizophrenia: breaking down the barrier. New York: John Wiley & Sons, 1996; 209-36
56. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54: 549-57
57. Arvanitis LA, Miller BG, Seroquel 13 Study Group. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233-46
58. Goldstein JM, Arvanitis LA, Cantillon M. Low incidence of reproductive/hormonal side effects with 'Seroquel' (quetiapine fumarate) is supported by its lack of elevation of plasma prolactin concentrations. 36th Annual Meeting of the American College of Neuropsychopharmacology: 1997 Dec: Honolulu
59. Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 1992; 10: 25-33
60. van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996; 124: 168-75
61. Seeger TF, Seymor PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101-13
62. 2 receptors by the neuroleptic ziprasidone (CP-88, 059-01) determined by positron emission tomography. Psychopharmacology 1996; 124: 141-7
63. Beaumont P, Bruwer J, Pimstone P, et al. Bromo-ergocryptine in the treatment of phenothiazine-induced galactorrhea. Br J Psychiatry 1975; 126: 285-8
64. Dorevitch A, Aronzon R, Stark M. Psychotic exacerbation attributed to low-dose bromocriptine treatment of galactorrhea and hyperprolactinemia. Acta Obstet Gynaecol Scand 1991; 70 (4-5): 375-6
65. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994 Oct 6; 331 (14): 904-9
66. Correa N, Opler LA, Kay SR. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol 1987; 7: 91-5
67. Siever LJ. The effect of amantadine on prolactin levels and galactorrhea in neuroleptic-treated patients. J Clin Psychopharmacol 1981; 1: 2-7
68. Physician's desk reference. Montvale (NJ): Medical Economics Company, 1998
69. Yamada K, Kanba S, Murata T, et al. Effectiveness of shakuyaku-kanzo-to in neuruleptic-induced hyperprolactinemia: a preliminary report. Psychiatry Clin Neurosci 1996; 50: 341-2